Drugs / Isoquercetin
Isoquercetin
also known as
PR1 · 3-glucosylquercetin · Contigoside b · Glucosyl-3-quercetin · Hirsutrin · Kinisoquin · NSC-115918 · Quercetin 3-d-glucoside · +8 more
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01722669 | May 2012 → Dec 2019 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00270452 | Dec 2005 → Oct 2007 | myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02446795 | Nov 2016 → Dec 2017 | renal cell carcinoma | Consorzio Oncotech | Unknown | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07303894 | Jan 2026 → Jan 2032 expected | malignant epithelial tumor of ovary, ovarian serous tumor | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04536090 | Jan → Dec 2022 | COVID-19 | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT04733651 | Feb → May 2021 | COVID-19 | Nepal Health Research Council | Unknown | No outcome recorded |
| Phase 2 | NCT04474626 | Dec 2020 → Dec 2022 | sickle cell disease, sickle cell-beta zero-thalassemia | Jeffrey Zwicker, MD | Withdrawn | No outcome recorded |
| Phase 2 | NCT04514510 | Nov 2020 → Jun 2022 | sickle cell disease | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT04622865 | Jun 2020 → Dec 2023 | COVID-19 | AB Science | Unknown | No outcome recorded |
| Phase 2 | NCT00415857 | Dec 2006 → Sep 2013 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02195232 | Jan 2015 → Dec 2018 | venous thromboembolism | Jeffrey Zwicker, MD | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06861088 | Dec 2025 → Oct 2027 expected | pancreatic adenocarcinoma, venous thromboembolism | Quercis Pharma AG | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02866448 | Aug → Oct 2016 | cardiovascular disorder | University of Reading | Withdrawn | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isoquercetin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04474626 ↗ |
| Known as | 3-glucosylquercetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Contigoside b | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Glucosyl-3-quercetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Hirsutrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Kinisoquin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06861088 ↗ |
| Known as | NSC-115918 | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | PR1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00415857 ↗ |
| Known as | Quercetin 3-d-glucoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin 3-o-glucopyranoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin 3-o-glucoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin 3.beta.-glucoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin glucoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin-3-glucose | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | quercetin-3-O-beta-D-glucoside | “Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.” NCT04514510 ↗ |
| Known as | Quercetol 3-monoglucoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Ronacare isoquercetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Action | Deplete | “The vaccines then activate the immune system to make specialized cells that search out and kill the MDS, AML and CML cells containing the two proteins.” NCT00270452 ↗ |
| Modality | Vaccine | “We describe the safety and immunogenicity of a combined vaccine of 2 leukemia-associated antigenic peptides, PR1 and WT1.” PMID 17875804 ↗ Sep 2007 |
| Route | Subcutaneous | “one subcutaneous dose each of PR1 and WT1 vaccines in Montanide adjuvant” PMID 17875804 ↗ Sep 2007 |